imho, now is the first opening in 2,000 years for a new, global ideology to emerge.

Don’t Die is the dark horse.

ty @micsolana and Peter Thiel for assembling @hereticon

Sources:

1.
2.
3.
4.
5.

The Ozempic advantage in preventing Alzheimer's disease seems to be independent of its weight reduction effect, as the Alzheimer's disease risk reduction extended to both obese and non-obese patients on Ozempic as compared to other type 2 diabetes medications.

Unlike between…

This shows potential for Ozempic and other GLP1 receptor agonists as potential longevity drugs beyond their role as diabetes and obesity medication, and warrants more credibility to earlier claims that focused only on obese patients. Ref (5)

Ozempic had better Alzheimer's disease protective advantage in women, and in the special case of SGLT2-inhibitors, the Ozempic advantage was exclusive in women, with SGLT2 inhibitors outperforming Ozempic slightly by 14% in Alzheimer's disease.

This is very intriguing in light…

While Ozempic also bestowed 47% relative risk reduction to women, other GLP-1 receptor agonists slightly outperformed Ozempic in men (14% relative Alzheimer's disease risk).

The study compared Semaglutide (Commercially: Ozempic for diabetes, Wegovy for weight-loss) against 7 other type 2 diabetes medications for its ability to prevent Alzheimer's disease in older type 2 diabetes patients, a critical group with 65% higher risk for developing…

Ozempic outperformed every other type 2 diabetes medication in preventing Alzheimer's disease, with a 78% and 52% risk reduction compared to insulin, in women and men, respectively.

Ozempic surpasses all other diabetes medications in preventing Alzheimer's disease in diabetics >60 years, effect is more pronounced in women, and independent of obesity.